Zacks Research Issues Negative Outlook for MMSI Earnings

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Zacks Research reduced their Q4 2024 earnings per share estimates for Merit Medical Systems in a note issued to investors on Wednesday, November 20th. Zacks Research analyst I. Bandyopadhyay now expects that the medical instruments supplier will earn $0.81 per share for the quarter, down from their previous estimate of $0.83. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.36 per share. Zacks Research also issued estimates for Merit Medical Systems’ Q3 2026 earnings at $1.07 EPS.

A number of other brokerages have also issued reports on MMSI. Barrington Research restated an “outperform” rating and set a $114.00 target price on shares of Merit Medical Systems in a research report on Thursday, October 31st. Robert W. Baird increased their price target on Merit Medical Systems from $107.00 to $109.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Piper Sandler restated an “overweight” rating and set a $110.00 price objective (up previously from $100.00) on shares of Merit Medical Systems in a research note on Monday, September 9th. StockNews.com downgraded Merit Medical Systems from a “buy” rating to a “hold” rating in a research report on Sunday, November 3rd. Finally, Needham & Company LLC restated a “buy” rating and issued a $109.00 price target on shares of Merit Medical Systems in a research report on Thursday, October 31st. Three analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Merit Medical Systems presently has an average rating of “Moderate Buy” and an average target price of $103.36.

Merit Medical Systems Trading Down 0.9 %

MMSI stock opened at $104.00 on Monday. Merit Medical Systems has a 52 week low of $65.46 and a 52 week high of $106.87. The company has a market capitalization of $6.06 billion, a PE ratio of 50.98, a price-to-earnings-growth ratio of 2.62 and a beta of 0.89. The company’s 50-day simple moving average is $98.81 and its 200 day simple moving average is $91.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.82 and a current ratio of 5.36.

Merit Medical Systems (NASDAQ:MMSI) last released its quarterly earnings results on Wednesday, October 30th. The medical instruments supplier reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.80 by $0.06. The business had revenue of $339.85 million during the quarter, compared to the consensus estimate of $334.60 million. Merit Medical Systems had a return on equity of 15.61% and a net margin of 9.05%. The firm’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.75 EPS.

Insider Activity

In related news, CFO Raul Jr. Parra sold 29,646 shares of the firm’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $98.02, for a total transaction of $2,905,900.92. Following the sale, the chief financial officer now owns 16,361 shares of the company’s stock, valued at $1,603,705.22. This trade represents a 64.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director F. Ann Millner sold 12,500 shares of the business’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $101.55, for a total value of $1,269,375.00. Following the sale, the director now owns 32,391 shares in the company, valued at $3,289,306.05. This represents a 27.85 % decrease in their position. The disclosure for this sale can be found here. 3.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Merit Medical Systems

Several hedge funds have recently added to or reduced their stakes in MMSI. FMR LLC lifted its holdings in shares of Merit Medical Systems by 70.1% during the third quarter. FMR LLC now owns 1,577,246 shares of the medical instruments supplier’s stock worth $155,879,000 after purchasing an additional 649,799 shares during the period. Point72 Asset Management L.P. lifted its position in shares of Merit Medical Systems by 147.2% in the 2nd quarter. Point72 Asset Management L.P. now owns 634,613 shares of the medical instruments supplier’s stock worth $54,545,000 after purchasing an additional 377,851 shares during the period. Two Sigma Advisers LP boosted its position in Merit Medical Systems by 218.9% during the third quarter. Two Sigma Advisers LP now owns 445,500 shares of the medical instruments supplier’s stock valued at $44,029,000 after acquiring an additional 305,800 shares during the last quarter. Iron Triangle Partners LP bought a new stake in shares of Merit Medical Systems during the 3rd quarter valued at about $25,004,000. Finally, International Assets Investment Management LLC bought a new position in shares of Merit Medical Systems during the 3rd quarter worth approximately $21,156,000. 99.66% of the stock is currently owned by institutional investors and hedge funds.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.